Amongst other novel formats, non-antibody protein scaffolds have emerged as viable alternatives to conventional therapies, having the capability to address the existing challenges associated with classical antibody based therapies. The ‘Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030’report provides a comprehensive study of the current market landscape of non-antibody protein scaffolds, and related drugs and diagnostics, featuring an elaborate discussion on the likely future potential of this upcoming market.Some of the most interesting insights from our study are presented below.
The Landscape of Non-Antibody Protein Scaffolds is Steadily Evolving With improved half-lives and better stability, several non-antibody protein scaffolds have emerged as potential alternatives to antibody therapeutics
Though the Field has Gained Traction Globally, Europe has Witnessed The Maximum Activity Along with small and mid-sized players, the field has seen efforts being made by several big pharma stakeholders; research activity is heavily concentrated in parts of Europe.
Research Efforts Have Already Led to Development of Many Novel Scaffolds … These novel scaffolds, driven by persistent research efforts, have shown remarkable potential in drug development.
… That Vary Across Different Evaluable Parameters Affibody® is currently the most popular non-antibody protein scaffold that has been used to design product candidates intended for both therapeutic and diagnostic purposes.
Strong Early Stage Pipeline Holds Significant Promise … EGFR, HER2, VEGF-A and TNF-α have been identified to be the most popular targets in this space; these are being investigated across various novel scaffold formats.
… To Treat Multiple Disease Indications With over 80 unique products catering to a wide array of disease indications, non-antibody protein scaffolds have gained significant traction within the pharma industry.
Growing Number of Partnerships Validates the Heavy Interest in This Area Over the years, several collaborations have also been established in this niche domain; majority of these are focused on R&D activities, followed by licensing deals
The Market is Expected to Gain Momentum in the Long Term Post the approval and launch of multiple late-phase product candidates, the market is expected to grow at a rapid pace.
The Opportunity Will be Well Distributed Across Key Therapeutic Areas The overall opportunity is likely to be well distributed across key products, based on different non-antibody protein scaffolds and target therapeutic areas
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.